Aselizumab, referred to as HuDreg-55, signifies a innovative monoclonal antibody engineered to bind to complement protein . How it works utilizes modulating the classical complement pathway, potentially https://aselizumabrecombinant399717.mpeblog.com/77385181/aselizumab-a-in-depth-analysis-into-hudreg-55